寻常性银屑病患者血清内脂素和内皮细胞钙黏蛋白的检测

中华皮肤科杂志 ›› 2011, Vol. 44 ›› Issue (4): 275-276.

寻常性银屑病患者血清内脂素和内皮细胞钙黏蛋白的检测

严旭¹,黄友敏²,马学良³

1. 山东省滕州市中心人民医院
2.
3. 山东省滕州市中心人民医院皮肤科

收稿日期:2010-08-04 修回日期:2010-09-21 出版日期:2011-04-15 发布日期:2011-04-01
通讯作者: 马学良 E-mail:liangzi666888@sina.com

Detection of serum visfatin and vascular endothelial cadherin （VE-cadherin） in patients with psoriasis vulgaris

Received:2010-08-04 Revised:2010-09-21 Online:2011-04-15 Published:2011-04-01

摘要/Abstract

摘要：

目的探讨血清内脂素和内皮细胞钙黏蛋白在寻常性银屑病发病中的作用及其临床意义。方法应用ELISA法检测78例寻常性银屑病患者治疗前后外周血清中内脂素和内皮细胞钙黏蛋白水平的变化及其与病情活动指标之间的关系。结果治疗前银屑病患者血清中内脂素和内皮细胞钙黏蛋白的水平较正常对照组显著增高（t值分别为10.53、10.16，P值均 < 0.01），进行期显著高于静止期（t值分别为12.47、13.11，P值均 < 0.01）。治疗后内脂素和内皮细胞钙黏蛋白较治疗前显著下降。内脂素的血清浓度变化与内皮细胞钙黏蛋白水平及银屑病严重程度指数PASI呈正相关（r = 0.58、0.64，P < 0.01）。结论血清内脂素和内皮细胞钙黏蛋白可作为寻常性银屑病病情活动的指标之一。

关键词: 内皮细胞钙黏蛋白

Abstract:

Objective To investigate the roles of serum visfatin and VE-cadherin in the pathogenesis of psoriasis vulgaris and their clinical significance. Methods Enzyme-linked immunosorbent assay （ELISA） was used to detect the serum levels of visfatin and VE-cadherin in 78 patients with psoriasis vulgaris before and after treatment and in 30 normal human controls. The relationship between the two parameters and disease activity was evaluated. Results The serum levels of visfatin and VE-cadherin were significantly higher in untreated patients with psoriasis than in the normal controls （t = 10.53, 10.16, both P < 0.01）, and in patients with active psoriasis than in those with stable psoriasis （t = 12.47, 13.11, both P < 0.01）. The treatment caused a marked decrease in the serum levels of visfatin and VE-cadherin in patients. The serum level of visfatin was positively associated with the level of VE-cadherin and PASI scores （r = 0.58, 0.64, P < 0.01） in patients with psoriasis. Conclusion Visfatin and VE-cadherin may be used as parameters for evaluating disease activity of psoriasis vulgaris.

Key words: VE-cadherin

严旭黄友敏马学良. 寻常性银屑病患者血清内脂素和内皮细胞钙黏蛋白的检测[J]. 中华皮肤科杂志, 2011, 44(4): 275-276.

参考文献

[1] Wetzel A, Wetzig T, Haustein UF, et al. Increased neutrophil adherence in psoriasis: role of the human endothelial cell receptorThy –1 (CD90). J Invest Dermatol, 2006, 126(2): 441-452. [2] Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol, 2007, 178(3): 1748-1758. [3] 徐永庆,吴春健,黄友敏. 血管内皮细胞钙黏蛋白在急性脑梗死诊断中的应用.中华急诊医学杂志, 20081, 7(8): 863-866. [4] 张学军主编. 皮肤性病学[M]. 北京: 人民卫生出版社, 2005: 129-130. [5] Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol, 2008, 69(6): 878-884. [6] Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis possible role in inflammation and plaque destabilization. Circulation, 2007, 115(8): 972-980. [7] Lim SY, Davidson SM, Paramanathan AJ, et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Mol Med, 2008, 12(4): 1395-1403. [8] Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signaling pathways: novel insights into visfatin induced angiogenesis. Cadiovasc Res, 2008, 78(2): 356-365. [9] Nusken KD, Petrasch M, Rauh M, et al. Active visfatin is elevated inserum ofmaintenance hemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant, 2009, 24(9): 832-838. [10] Kim SR, Bae YH, Bae SK, et al Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim BiophysActa, 2008, 1783 (5): 886-895. [11] Taveau JC, Dubois M, Le Bihan O, et al. Structure of artificial and natural VE-cadherin-based adherens junctions. Biochem Soc Trans, 2008, 36(Pt 2): 189-193. [12] Guo M, Breslin JW, Wu MH, et al. VE-cadherin and beta-catenin binding dynamics during histamine- induced endothelial hyperpermeability. Am J Physiol Cell Physiol, 2008, 294(4): 977-984. [13] Rudini N, Felici A，Giampietro C, et al. VE-cadherin is a critical endothelial regulator of TGF-beta signaling. EMBO J, 2008, 27(7): 993-1004. [14] Heupel WM, Efthymiadis A, Schlegel N, et al. Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo. J Cell Sci, 2009, 122(Pt 10): 1616-1625. [15] 李莉，黄友敏. 急性颅脑损伤后血管内皮细胞钙黏蛋白和精氨酸加压素的动态变化. 中华急诊医学杂志, 2009，18(12), 1266-1269.